earnings
confidence high
sentiment positive
materiality 0.70
Abbott Q2 adjusted EPS $1.26, sales $11.14B (+7.4%); guides FY adjusted EPS $5.10-$5.20
ABBOTT LABORATORIES
2025-Q2 EPS reported
$1.77
revenue$21,500,000,000
- GAAP diluted EPS $1.01; adjusted diluted EPS $1.26, double-digit growth YoY.
- Total reported sales $11.14B, +7.4% reported, +6.9% organic, +7.5% ex-COVID tests.
- Medical Devices organic growth 12.2%; Diabetes Care CGM sales $1.9B, +19.6% organic.
- Full-year 2025 guidance: organic sales growth ex-COVID 7.5%-8.0%; adjusted EPS $5.10-$5.20.
- Q3 2025 adjusted diluted EPS guidance $1.28-$1.32; adjusted operating margin ~23.5% for FY.
item 2.02item 9.01